Literature DB >> 30311425

Complete but not partial inhibition of glutamate transporters exacerbates cortical excitability in the R6/2 mouse model of Huntington's disease.

Ana María Estrada-Sánchez1, Daniel Castro1, Kenia Portillo-Ortiz1, Katrina Jang1, Michael Nedjat-Haiem1, Michael S Levine1, Carlos Cepeda1.   

Abstract

AIM: Deficient glutamate reuptake occurs in the cerebral cortex of Huntington's disease (HD) patients and murine models. Here, we examine the effects of partial or complete blockade of glutamate transporters on excitatory postsynaptic currents (EPSCs) of cortical pyramidal neurons (CPNs).
METHODS: Whole-cell patch clamp recordings of CPNs in slices from symptomatic R6/2 mice and wild-type (WT) littermates were used to examine the effects of selective or concurrent inhibition of glutamate reuptake transporters.
RESULTS: Selective inhibition of the glial glutamate transporter 1 (GLT-1) or the glutamate aspartate transporter (GLAST) produced slight decreases in decay time of evoked EPSCs in CPNs from WT and R6/2 mice with no significant differences between genotypes. In contrast, concurrent inhibition of both transporters with DL-TBOA induced a significant increase in area and decay time and this effect was significantly greater in R6/2 CPNs. Furthermore, full blockade also reduced spontaneous EPSC frequency and exacerbated epileptiform activity in CPNs from symptomatic R6/2 mice.
CONCLUSIONS: R6/2 CPNs are more sensitive to glutamate accumulation during full inhibition of both glutamate transporters, and these neurons have homeostatic mechanisms to cope with inhibition of GLT-1 or GLAST by a mechanism that involves upregulation of either transporter when the other is deficient.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  Astrocytes; Cerebral cortex; Glutamate transporters; Paroxysmal activity

Mesh:

Substances:

Year:  2018        PMID: 30311425      PMCID: PMC6428599          DOI: 10.1111/cns.13070

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  57 in total

1.  Glutamate uptake is reduced in prefrontal cortex in Huntington's disease.

Authors:  Bjørnar Hassel; Shoshi Tessler; Richard L M Faull; Piers C Emson
Journal:  Neurochem Res       Date:  2007-08-29       Impact factor: 3.996

Review 2.  Molecular mechanisms of homeostatic synaptic downscaling.

Authors:  Benjamin Siddoway; Hailong Hou; Houhui Xia
Journal:  Neuropharmacology       Date:  2013-08-02       Impact factor: 5.250

3.  Complete but not partial inhibition of glutamate transporters exacerbates cortical excitability in the R6/2 mouse model of Huntington's disease.

Authors:  Ana María Estrada-Sánchez; Daniel Castro; Kenia Portillo-Ortiz; Katrina Jang; Michael Nedjat-Haiem; Michael S Levine; Carlos Cepeda
Journal:  CNS Neurosci Ther       Date:  2018-10-11       Impact factor: 5.243

4.  Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.

Authors:  Tim Indersmitten; Conny H Tran; Carlos Cepeda; Michael S Levine
Journal:  J Neurophysiol       Date:  2015-02-11       Impact factor: 2.714

5.  Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation.

Authors:  P F Behrens; P Franz; B Woodman; K S Lindenberg; G B Landwehrmeyer
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

6.  Activity differentially regulates the surface expression of synaptic AMPA and NMDA glutamate receptors.

Authors:  D V Lissin; S N Gomperts; R C Carroll; C W Christine; D Kalman; M Kitamura; S Hardy; R A Nicoll; R C Malenka; M von Zastrow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

7.  Characterization of novel L-threo-beta-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters.

Authors:  Keiko Shimamoto; Ryuichi Sakai; Kiyo Takaoka; Noboru Yumoto; Terumi Nakajima; Susan G Amara; Yasushi Shigeri
Journal:  Mol Pharmacol       Date:  2004-04       Impact factor: 4.436

8.  In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects.

Authors:  Mathilde Faideau; Jinho Kim; Kerry Cormier; Richard Gilmore; Mackenzie Welch; Gwennaelle Auregan; Noelle Dufour; Martine Guillermier; Emmanuel Brouillet; Philippe Hantraye; Nicole Déglon; Robert J Ferrante; Gilles Bonvento
Journal:  Hum Mol Genet       Date:  2010-05-21       Impact factor: 6.150

9.  Single synapse evaluation of the postsynaptic NMDA receptors targeted by evoked and spontaneous neurotransmission.

Authors:  Austin L Reese; Ege T Kavalali
Journal:  Elife       Date:  2016-11-24       Impact factor: 8.140

10.  Differential Synaptic and Extrasynaptic Glutamate-Receptor Alterations in Striatal Medium-Sized Spiny Neurons of Aged YAC128 Huntington's Disease Mice.

Authors:  Eliã P Botelho; Elizabeth Wang; Jane Y Chen; Sandra Holley; Veronique Andre; Carlos Cepeda; Michael S Levine
Journal:  PLoS Curr       Date:  2014-05
View more
  4 in total

1.  Complete but not partial inhibition of glutamate transporters exacerbates cortical excitability in the R6/2 mouse model of Huntington's disease.

Authors:  Ana María Estrada-Sánchez; Daniel Castro; Kenia Portillo-Ortiz; Katrina Jang; Michael Nedjat-Haiem; Michael S Levine; Carlos Cepeda
Journal:  CNS Neurosci Ther       Date:  2018-10-11       Impact factor: 5.243

2.  Synaptic Dysfunction in Huntington's Disease: Lessons from Genetic Animal Models.

Authors:  Carlos Cepeda; Michael S Levine
Journal:  Neuroscientist       Date:  2020-11-16       Impact factor: 7.235

Review 3.  Huntington's disease mouse models: unraveling the pathology caused by CAG repeat expansion.

Authors:  Julia Kaye; Terry Reisine; Steve Finkbeiner
Journal:  Fac Rev       Date:  2021-10-21

Review 4.  Altered Cholesterol Homeostasis in Huntington's Disease.

Authors:  Radhia Kacher; Coline Mounier; Jocelyne Caboche; Sandrine Betuing
Journal:  Front Aging Neurosci       Date:  2022-04-19       Impact factor: 5.750

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.